Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Lipids: Dietary Sources and Requirements

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Central- and peripheral-line-associated bloodstream infections in Victorian neonatal intensive care units: findings from a comprehensive Victorian surveillance network, 2008-2024.

The Journal of hospital infection·2025

Same author

'Closing the gap': Evaluating the success of non-mandatory strategies for influenza vaccination of Victorian healthcare workers.

Vaccine·2020

Same author

Analytical performance of HPV assays on vaginal self-collected vs practitioner-collected cervical samples: the SCoPE study.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2020

Same author

Association of endothelial lipase Thr111Ile polymorphism with proliferative retinopathy in type 2 diabetes patients.

Diabetes & metabolism·2014

Same author

Evaluation of the training and support received by facilitators of a cancer education and support programme in New Zealand.

European journal of cancer care·2011

Same author

Association of endothelial lipase Thr111Ile polymorphism with lipid metabolism and microvascular complications in type 2 diabetic patients.

Diabetes & metabolism·2010

Search research articles

Related Experiment Video

Updated: Jul 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Treatment of hyperlipidemia.

J P Kane¹, M J Malloy

¹Department of Medicine, University of California, San Francisco 94143-0130.

Annual Review of Medicine

|January 1, 1990

Summary

Reducing atherogenic lipoproteins in blood is key to preventing atherosclerotic disease. New therapies effectively lower lipoprotein levels, improving outcomes for many patients.

Area of Science:

Cardiovascular Medicine
Lipid Metabolism
Pharmacotherapy

Background:

Atherosclerosis development involves lipoprotein uptake by artery wall scavenger cells.
Plasma lipoprotein concentrations directly correlate with atherosclerosis risk.
Reducing atherogenic lipoproteins in blood is the primary therapeutic strategy.

Purpose of the Study:

To outline the rationale for managing atherosclerotic disease through lipoprotein reduction.
To highlight recent therapeutic advancements enabling effective lipoprotein level management.
To guide rational drug selection and treatment decisions for hyperlipoproteinemia.

Main Methods:

Review of intervention trial data supporting lipoprotein reduction.
Analysis of therapeutic advances, including HMG CoA reductase inhibitors and combination drug regimens.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jul 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Emphasis on phenotypic characterization for personalized treatment strategies.

Consideration of secondary hyperlipoproteinemia and lifestyle interventions (diet).

Main Results:

Intervention trials demonstrate reduced coronary disease progression and mortality with lipoprotein-lowering therapies.
Current therapies allow optimal reduction of plasma lipoprotein levels in most individuals.
Phenotypic assessment facilitates rational selection of drug regimens.

Conclusions:

Effective management of atherosclerotic disease relies on reducing atherogenic lipoproteins.
Modern pharmacotherapy, guided by phenotypic assessment, offers significant treatment potential.
Dietary intervention and management of secondary causes are crucial components of comprehensive care.